171 related articles for article (PubMed ID: 10802777)
1. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators.
Wolinsky JS; Narayana PA; Noseworthy JH; Lublin FD; Whitaker JN; Linde A; Gjörstrup P; Sullivan HC
Neurology; 2000 May; 54(9):1734-41. PubMed ID: 10802777
[TBL] [Abstract][Full Text] [Related]
2. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators.
Noseworthy JH; Wolinsky JS; Lublin FD; Whitaker JN; Linde A; Gjorstrup P; Sullivan HC
Neurology; 2000 May; 54(9):1726-33. PubMed ID: 10802775
[TBL] [Abstract][Full Text] [Related]
3. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials.
Tan IL; Lycklama à Nijeholt GJ; Polman CH; Adèr HJ; Barkhof F
Mult Scler; 2000 Apr; 6(2):99-104. PubMed ID: 10773855
[TBL] [Abstract][Full Text] [Related]
4. Lessons from linomide: a failed trial, but not a failure.
Schwid SR; Trotter JL
Neurology; 2000 May; 54(9):1716-7. PubMed ID: 10802772
[No Abstract] [Full Text] [Related]
5. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation.
Karussis DM; Meiner Z; Lehmann D; Gomori JM; Schwarz A; Linde A; Abramsky O
Neurology; 1996 Aug; 47(2):341-6. PubMed ID: 8757002
[TBL] [Abstract][Full Text] [Related]
6. Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis.
Whitaker JN; Wolinsky JS; Narayana PA; Bartolucci AA; Noseworthy JH; Lublin FD; Linde A; Gjörstrup P; Sullivan HC;
Arch Neurol; 2001 Jan; 58(1):49-54. PubMed ID: 11176936
[TBL] [Abstract][Full Text] [Related]
7. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.
Andersen O; Lycke J; Tollesson PO; Svenningsson A; Runmarker B; Linde AS; Aström M; Gjörstrup P; Ekholm S
Neurology; 1996 Oct; 47(4):895-900. PubMed ID: 8857715
[TBL] [Abstract][Full Text] [Related]
8. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years.
Turner B; Lin X; Calmon G; Roberts N; Blumhardt LD
Mult Scler; 2003 Feb; 9(1):21-7. PubMed ID: 12617263
[TBL] [Abstract][Full Text] [Related]
9. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
[TBL] [Abstract][Full Text] [Related]
10. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
[TBL] [Abstract][Full Text] [Related]
11. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.
Horakova D; Cox JL; Havrdova E; Hussein S; Dolezal O; Cookfair D; Dwyer MG; Seidl Z; Bergsland N; Vaneckova M; Zivadinov R
J Neurol Neurosurg Psychiatry; 2008 Apr; 79(4):407-14. PubMed ID: 17550987
[TBL] [Abstract][Full Text] [Related]
12. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
13. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
Sormani MP; Stubinski B; Cornelisse P; Rocak S; Li D; De Stefano N
Mult Scler; 2011 May; 17(5):541-9. PubMed ID: 21148262
[TBL] [Abstract][Full Text] [Related]
15. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale.
Bakshi R; Neema M; Healy BC; Liptak Z; Betensky RA; Buckle GJ; Gauthier SA; Stankiewicz J; Meier D; Egorova S; Arora A; Guss ZD; Glanz B; Khoury SJ; Guttmann CR; Weiner HL
Arch Neurol; 2008 Nov; 65(11):1449-53. PubMed ID: 19001162
[TBL] [Abstract][Full Text] [Related]
16. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
17. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
Zivadinov R; Rudick RA; De Masi R; Nasuelli D; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
Neurology; 2001 Oct; 57(7):1239-47. PubMed ID: 11591843
[TBL] [Abstract][Full Text] [Related]
18. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
[TBL] [Abstract][Full Text] [Related]
19. A randomized crossover study of bee sting therapy for multiple sclerosis.
Wesselius T; Heersema DJ; Mostert JP; Heerings M; Admiraal-Behloul F; Talebian A; van Buchem MA; De Keyser J
Neurology; 2005 Dec; 65(11):1764-8. PubMed ID: 16221950
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation with linomide: possible novel therapy for multiple sclerosis.
Abramsky O; Lehmann D; Karussis D
Mult Scler; 1996 Nov; 2(4):206-10. PubMed ID: 9345375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
